Boardroom Alpha
Boardroom Alpha
G · Current Report (Form 8-K) · Filed November 18, 2025

Genpact Ltd — Current Report (Form 8-K)

Form
8-K
Filed
November 18, 2025
Period
Nov 18, 2025
Ticker
G
Accession
0001140361-25-042599
Boardroom Alpha · Filing insights

Genpact completed a $350M 2030 notes offering, guaranteed by Genpact and Genpact Luxembourg. Proceeds for general corporate purposes.

About Genpact Ltd
Market cap
$5.6B
1Y TSR
−23.7%
3Y TSR
−3.7%
Board grade
C+
Sector
Technology
CEO
Balkrishan Kalra
Last annual meeting: Apr 23, 2026 · View full Genpact Ltd profile →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

 CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 18, 2025

GENPACT LIMITED
(Exact name of registrant as specified in its charter)

Bermuda
001-33626
98-0533350
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

Canon's Court, 22 Victoria Street
Hamilton HM 12, Bermuda
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (441) 298-3300
Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol
Name of each exchange on which registered
Common shares, par value $0.01 per share
G
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 1.01.
Entry into a Material Definitive Agreement.

Notes Offering

On November 18, 2025, Genpact UK Finco plc (“Genpact UK”) and Genpact USA, Inc. (“Genpact USA”), indirect wholly owned subsidiaries of Genpact Limited (“Genpact”), completed their previously announced underwritten public offering (the “Notes Offering”) of $350 million aggregate principal amount of their 4.950% Senior Notes due 2030 (the “2030 Notes”). The 2030 Notes are Genpact UK’s and Genpact USA’s senior unsecured indebtedness and are guaranteed on a senior unsecured basis by Genpact and Genpact Luxembourg S.à r.l. (“Genpact Luxembourg”). The 2030 Notes were issued pursuant to an indenture dated as of November 18, 2025 (the “Base Indenture”) among Genpact UK, Genpact USA, Genpact, Genpact Luxembourg and Computershare Trust Company, National Association, as trustee (the “Trustee”), and a first supplemental indenture dated as of November 18, 2025 (the “First Supplemental Indenture”).

The 2030 Notes have been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291491), as supplemented by the prospectus supplement dated November 13, 2025, filed with the Securities and Exchange Commission under the Securities Act.

In connection with the issuance of the 2030 Notes, Genpact, Genpact UK, Genpact USA and Genpact Luxembourg entered into an Underwriting Agreement dated as of November 13, 2025 (the “Underwriting Agreement”), among Genpact UK and Genpact USA, as co-issuers, Genpact and Genpact Luxembourg, as guarantors, and the representatives of the several underwriters named therein (the “Underwriters”), pursuant to which Genpact UK and Genpact USA agreed to issue and sell the 2030 Notes to the Underwriters. For a complete description of the terms and conditions of the Underwriting Agreement, please refer to the Underwriting Agreement, which is filed as Exhibit 1.1 hereto, and is incorporated herein by reference.

The 2030 Notes will mature on November 18, 2030. Interest on the 2030 Notes accrues at the rate of 4.950% per annum and is payable semi-annually in arrears on May 18 and November 18 of each year, commencing on May 18, 2026.

The 2030 Notes and the related guarantees are general unsecured obligations of Genpact UK, Genpact USA, Genpact and Genpact Luxembourg, as applicable, and will be pari passu in right of payment with all existing and future senior indebtedness of such entities, will be effectively subordinated to all future secured indebtedness of such entities to the extent of the value of the assets securing that indebtedness and will be senior in right of payment to all future subordinated indebtedness of such entities. The 2030 Notes will be structurally subordinated to all indebtedness and other liabilities of subsidiaries of Genpact (other than Genpact UK, Genpact USA and Genpact Luxembourg) that do not guarantee the 2030 Notes, including the liabilities of certain subsidiaries pursuant to Genpact’s senior credit facility.

Genpact UK and Genpact USA may redeem some or all of the 2030 Notes prior to October 18, 2030 at a redemption price equal to 100% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the redemption date, plus an applicable “make-whole” premium. Genpact UK and Genpact USA may redeem some or all of the 2030 Notes on or after October 18, 2030 at a redemption price equal to 100% of their principal amount, plus accrued and unpaid interest, if any, to, but not including, the redemption date.


The 2030 Notes are subject to certain customary covenants, including limitations on the ability of Genpact and certain of its subsidiaries, including Genpact UK and Genpact USA, with significant exceptions, (i) to incur debt secured by liens; (ii) to engage in certain sale and leaseback transactions; and (iii) to consolidate, merge, convey or transfer their assets substantially as an entirety. In addition, pursuant to a customary change of control covenant, upon a change of control repurchase event, Genpact UK and Genpact USA will be required to make an offer to repurchase the 2030 Notes at a price equal to 101% of the aggregate principal amount of such 2030 Notes, plus accrued and unpaid interest, if any, to, but not including, the date of repurchase.

Genpact intends to use the net proceeds from the Notes Offering for general corporate purposes, which may include repaying or redeeming Genpact Luxembourg’s and Genpact USA’s outstanding 1.750% senior notes due 2026 (the “2026 Notes”) at or prior to their maturity on April 10, 2026.

Third Supplemental Indenture to 2021 Base Indenture

On November 18, 2025, Genpact Luxembourg, Genpact USA, Genpact, Genpact UK and the Trustee entered into a third supplemental indenture to the indenture dated as of March 26, 2021 among Genpact Luxembourg, Genpact USA, Genpact and the Trustee (the “2021 Base Indenture”), pursuant to which Genpact UK agreed to fully and unconditionally guarantee all of the 2026 Notes and all of Genpact Luxembourg’s and Genpact USA’s 6.000% senior notes due 2029 (the “2029 Notes”) (the “2021 Third Supplemental Indenture”) on the terms, and subject to the conditions and limitations set forth in, the 2021 Base Indenture.

The foregoing descriptions of the Base Indenture, the First Supplemental Indenture, the 2030 Notes and the 2021 Third Supplemental Indenture are qualified in their entirety by reference to the actual terms of the respective documents. Copies of the Underwriting Agreement, the Base Indenture, the First Supplemental Indenture, the form of the 2030 Notes and the 2021 Third Supplemental Indenture are attached as Exhibits 1.1, 4.1, 4.2, 4.3 and 4.4 hereto, respectively, and each is incorporated by reference herein.

Supplement to Guarantee the Credit Agreement

On November 18, 2025, Genpact UK entered into a guaranty supplement with Wells Fargo Bank, National Association, as administrative agent (the “Administrative Agent”), pursuant to which Genpact UK became a guarantor of the second amended and restated credit agreement, dated as of December 13, 2022, among Genpact USA, Genpact Global Holdings (Bermuda) Limited, Genpact Luxembourg and Genpact, as borrowers, the Administrative Agent and the lenders and other parties thereto.

Item 2.03.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information contained in Item 1.01 is incorporated by reference in this Item 2.03.


Item 9.01
Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit
No.
Description
   
Underwriting Agreement, dated as of November 13, 2025, among Genpact UK and Genpact USA, as co-issuers, Genpact and Genpact Luxembourg, as guarantors, and Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC, as representatives of the Underwriters.
   
Indenture, dated as of November 18, 2025, by and among Genpact UK, Genpact USA, Genpact, Genpact Luxembourg and Computershare Trust Company, National Association, as trustee.
   
First Supplemental Indenture, dated as of November 18, 2025, by and among Genpact UK, Genpact USA, Genpact and Genpact Luxembourg and Computershare Trust Company, National Association, as trustee.
   
Form of 4.950% Senior Note due 2030 (included as Exhibit A to the First Supplemental Indenture filed as Exhibit 4.2).
   
Third Supplemental Indenture, dated as of November 18, 2025, by and among Genpact Luxembourg, Genpact USA, Genpact, Genpact UK and Computershare Trust Company, National Association (as successor to Wells Fargo Bank, National Association), as trustee.
   
Opinion of Cravath, Swaine & Moore LLP.
   
Opinion of Allen Overy Shearman Sterling SCS société en commandite simple (inscrite au barreau de Luxembourg).
   
Opinion of Appleby (Bermuda) Limited.
   
Opinion of Slaughter and May.
   
Consent of Cravath, Swaine & Moore LLP (included in Exhibit 5.1).
   
Consent of Allen Overy Shearman Sterling SCS société en commandite simple (inscrite au barreau de Luxembourg) (included in Exhibit 5.2).
   
Consent of Appleby (Bermuda) Limited (included in Exhibit 5.3).
   
Consent of Slaughter and May (included in Exhibit 5.4).
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Schedules or similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Genpact hereby undertakes to furnish copies of any of the omitted schedules or similar attachments upon request by the Securities and Exchange Commission.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
GENPACT LIMITED
     
 
By:
/s/ Heather White
 
Name:
Heather White
 
Title:
Senior Vice President, Chief Legal Officer and Corporate Secretary

Dated: November 18, 2025

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Genpact Ltd (G)

Reference

Frequently asked questions

When did Genpact Ltd file this 8-K?
Genpact Ltd (G) filed this Current Report (Form 8-K) with the SEC on November 18, 2025. The accession number assigned by EDGAR is 0001140361-25-042599.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Genpact completed a $350M 2030 notes offering, guaranteed by Genpact and Genpact Luxembourg. Proceeds for general corporate purposes. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Genpact Ltd's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Genpact Ltd has filed under CIK 1398659, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer